OCULAR THERAPEUTIX ($OCUL) posted quarterly earnings results for Q3 2026 on Monday, November 9th. The company reported earnings of -$0.42 per share, missing estimates of -$0.37 by $0.05. The company also reported revenue of $12,870,000, missing estimates of $14,625,953 by $-1,755,953.
You can see Quiver Quantitative's $OCUL stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
OCULAR THERAPEUTIX Insider Trading Activity
OCULAR THERAPEUTIX insiders have traded $OCUL stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $OCUL stock by insiders over the last 6 months:
- PRAVIN DUGEL (See Remarks) has made 0 purchases and 2 sales selling 42,805 shares for an estimated $406,638.
- JEFFREY S. HEIER (Chief Scientific Officer) has made 0 purchases and 3 sales selling 17,183 shares for an estimated $136,904.
- PETER KAISER (Chief Development Officer) has made 0 purchases and 3 sales selling 15,992 shares for an estimated $127,445.
- NADIA WAHEED (Chief Medical Officer) sold 14,828 shares for an estimated $122,627
- TODD ANDERMAN (Chief Legal Officer) sold 11,984 shares for an estimated $87,363
- SANJAY NAYAK (Chief Strategy Officer) has made 0 purchases and 2 sales selling 3,755 shares for an estimated $35,685.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
OCULAR THERAPEUTIX Hedge Fund Activity
We have seen 123 institutional investors add shares of OCULAR THERAPEUTIX stock to their portfolio, and 122 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALLIANCEBERNSTEIN L.P. removed 3,902,667 shares (-94.5%) from their portfolio in Q2 2026, for an estimated $38,324,189
- BLACKROCK, INC. added 3,243,624 shares (+20.1%) to their portfolio in Q2 2026, for an estimated $31,852,387
- DELTEC ASSET MANAGEMENT LLC added 2,623,597 shares (+inf%) to their portfolio in Q3 2026, for an estimated $20,122,988
- COMMODORE CAPITAL LP removed 2,575,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $25,286,500
- POINT72 ASSET MANAGEMENT, L.P. removed 2,242,792 shares (-40.5%) from their portfolio in Q2 2026, for an estimated $22,024,217
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,726,384 shares (+29.3%) to their portfolio in Q2 2026, for an estimated $16,953,090
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,550,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $15,221,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
OCULAR THERAPEUTIX Price Targets
Multiple analysts have issued price targets for $OCUL recently. We have seen 3 analysts offer price targets for $OCUL in the last 6 months, with a median target of $25.0.
Here are some recent targets:
- Andreas Argyrides from Chardan Capital set a target price of $23.0 on 06/25/2026
- Colleen Kusy from Baird set a target price of $30.0 on 06/18/2026
- Yi Chen from HC Wainwright & Co. set a target price of $25.0 on 06/18/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
